



John B. Moore
Associate General Counsel

Office: (612) 632-6155
Mobile: (502) 594-7204
john.moore@optum.com

September 2, 2025

Tracey Woods
Agency Sourcing Manager
Department of Administrative Services
Via email: Tracey.woods1@doas.ga.gov

RE: Review of redaction requests, response to RFP 41900-DCH0000136

Dear Ms. Woods:

I am writing in follow-up to the phone call on August 26, 2025 during which the legal and business teams of Optum Rx and your office (referred to herein as "the State") discussed Optum Rx's supplemental confidentiality designations and document redactions submitted in response to the above RFP. In keeping with that call, please accept this letter as the requested clarification of my previous letter dated May 2, 2025 on this subject.

In your email dated April 11, 2025 to Jeffrey A. Gottlieb of Optum Rx, Inc. you asked that Optum Rx review and reconsider its redactions to documents previously submitted in response to the above RFP. In a good faith effort to comply with the requests made in your email, as well as the applicable provisions of Georgia law and the instructions provided with the RFP, Optum Rx subsequently withdrew many redactions and modified others. For the redactions that remained, we provided greater detail, including statutory references, in support of those redactions. However, Optum Rx's language designating some documents or data as Confidential, Proprietary, and Trade Secret Information remained on some documents despite our removal of previous redactions. To reiterate the explanation from my previous letter, the purpose for leaving that language was to preserve Optum Rx's rights to object to disclosure of the records pursuant to O.C.G.A. § 10-1-760 should we receive notice of a third-party request for disclosure as contemplated by that statute. Furthermore, we sought to preserve Optum's ability to claim exemption from disclosure in other jurisdictions where different laws or definitions may apply to the materials at issue here. In short, we did not want our agreement to reconsider and modify some prior redactions to be viewed as a waiver of Optum Rx's belief, or of its right to claim in a different proceeding or venue, that such materials remain Confidential, Proprietary, and Trade Secret Information notwithstanding the fact that they may be subject to disclosure under Georgia law.

CONFIDENTIAL, PROPRIETARY, AND TRADE SECRET INFORMATION OF OPTUM RX

Nevertheless, in order to provide further clarification, Optum Rx acknowledges and understands that under the RFP instructions, any records supplied in response to the RFP that are **not** redacted remain subject to disclosure pursuant to a proper third-party request despite the fact that they may be marked as Confidential, Proprietary, and Trade Secret Information of Optum Rx.

If you have any questions, or if I can provide any further clarification, please do not hesitate to contact me.

Sincerely,

A handwritten signature in black ink, appearing to read 'John B. Moore', with a stylized, cursive script.

John B. Moore